


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims

Claim 1 (currently amended) A compound of the formula I:




wherein:

R¹ is selected from the group consisting of:




R² is selected from the group consisting of:


- (1) R⁴-S(O)_m-NR⁵-,
- (2) R⁴-S(O)_m-,
- (3) R⁴NHCO-,
- (4) R⁴CONH-,
- (5) R⁴R⁵N-,
- (6) nitrile,
- (7) NC- C₁₋₆alkyl-,
- (8) halogen,
- (9)



(10)



R³ is selected from the group consisting of:



R⁴ is selected from the group consisting of:

- (1) hydrogen,
- (2) C₁₋₆alkyl,
- (3) phenyl, and
- (4) benzyl;

R⁵ is independently selected from the group consisting of:


- (1) hydrogen;
- (2) C₁₋₆alkyl,
- (3) phenyl,
- (4) benzyl, and

R^{6a}, R^{6b}, and R^{6c} are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3) -OR⁵,
- (4) -SR⁵, and
- (5) C₁₋₆alkyl;

R⁷ is selected from the group consisting of -C=C-, O, S, and NH;

Z is selected from the group consisting of CO, CH-OH, CH-F and



R^{8a} and R^{8b} are independently selected from the group consisting of:

- (1) nitrile
- (2) hydrogen,
- (3) halogen,
- (4) -OR⁵,
- (5) -SR⁵,
- (6) C₁₋₆alkyl,
- (7) -CO₂R⁵, and
- (8) tetrazolyl;

X¹ is hydrogen and X² is hydroxyl, ~~or X¹ and X² together form oxo;~~

n is independently 1, 2, 3, or 4;

m is independently 0, 1, or 2;

and pharmaceutically acceptable salts thereof.


Claim 2 (Canceled)

Claim 3 (Canceled)

Claim 4 (Canceled)

Claim 5 (Canceled)


Claim 6 (currently amended) The compound of Claim 1 wherein ~~R¹~~ is:



and wherein:


R⁵ is hydrogen or methyl;

Z is selected from the group consisting of CO, CH-OH, and



and pharmaceutically acceptable salts thereof.

Claim 7 (Original) The compound of Claim 1 wherein R² is:



and wherein R⁴ is selected from the group consisting of:


- (1) hydrogen,
- (2) C₁₋₆alkyl,
- (3) phenyl, and
- (4) benzyl;

R⁵ is selected from the group consisting of:

- (1) C₁₋₆alkyl,
- (2) phenyl,
- (3) benzyl, and
- (4) hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 8 (Original) The compound of Claim 1 wherein R³ is:



and wherein:


R⁴ is methyl;

R^{6a} is H or F;

R^{6b} and R^{6c} are hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 9 (Original) The compound of Claim 1 wherein R³ is:



wherein:


R⁵ is methyl;


R⁷ is O or NH;

and pharmaceutically acceptable salts thereof.

Claim 10 (Canceled).

Claim 11 (currently amended) The compound of Claim 3 which is selected from the group consisting of:





and pharmaceutically acceptable salts thereof.

Claim 12 (Original) A compound of Claim 1 in substantially diastereomerically pure form.

Claim 13 (Original) A substantially diastereomerically pure compound of Claim 1 in substantially enantiomerically pure form.

Claim 14 (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 15 (currently amended) A method for inhibition of ~~α -secretase~~ β -secretase activity in a mammal which comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

Claim 16 (Cancelled)

Claim 17 (Original) A method for treating, preventing, controlling, ameliorating or reducing the risk of Alzheimers disease in a patient comprising the administration to the patient of a therapeutically effective amount of a compound of Claim 1.